CALL US: 1-855-483-4325

A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events


The purpose of this trial is to compare the cardiovascular safety of insulin degludec to that of insulin glargine. Both are long acting insulin (basal insulin) products. Insulin degludec is produced by Novo Nordisk. Insulin degludec has not been approved by the U.S. Food and Drug Administration (FDA) and is considered experimental in this trial. For more information please contact Sarah Long at 352-273-8932 or at


insulin, cardiovasucular, diabetes

Principal Investigator

Margaret C Lo, M.D.



Contact Information
(352) 265-0140

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at

Other Resources

  • Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams